Related Experiment Video
Updated: Feb 3, 2026
Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
Published on: May 6, 2014
New Antibiotics for Pneumonia
Matteo Bassetti1, Elda Righi1, Alessandro Russo1
1Infectious Diseases Clinic, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria, Presidio Ospedaliero Universitario Santa Maria della Misericordia, Colugna Street, Udine 33100, Italy.
Abstract:
Delayed antimicrobial prescriptions and inappropriate treatment can lead to poor outcomes in pneumonia. In nosocomial infections, especially in countries reporting high rates of antimicrobial resistance, the presence of multidrug-resistant gram-negative and gam-positive bacteria can limit options for adequate antimicrobial treatment. New antibiotics, belonging to known classes of antimicrobials or characterized by novel mechanisms of actions, have recently been approved or are under development. Advantages of the new compounds include enhanced spectrum of activity against resistant bacteria, high lung penetration, good tolerability, and possibility for intravenous to oral sequential therapy. This article reviews characteristics of newly approved and investigational compounds.
Insights
New antibiotics offer improved treatment options for pneumonia, especially against resistant bacteria. These novel drugs show promise for better patient outcomes and flexible treatment strategies.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Delayed antimicrobial prescriptions and inappropriate treatment negatively impact pneumonia outcomes.
- Nosocomial infections, particularly in high antimicrobial resistance regions, present challenges due to multidrug-resistant bacteria.
- Limited effective antimicrobial options exist for certain resistant bacterial infections.
Purpose of the Study:
- To review the characteristics of newly approved and investigational antibiotics for pneumonia.
- To highlight agents with enhanced activity against resistant pathogens.
- To discuss the potential benefits of novel antimicrobial compounds.
Main Methods:
- Review of recently approved antimicrobial agents.
- Analysis of investigational compounds in development for pneumonia.
- Evaluation of antibiotic properties such as spectrum of activity, lung penetration, and tolerability.
Main Results:
- New antibiotics demonstrate broader activity against resistant gram-negative and gram-positive bacteria.
- Compounds exhibit favorable pharmacokinetic profiles, including high lung penetration.
- Potential for intravenous to oral sequential therapy is a key advantage.
Conclusions:
- Novel antibiotics provide crucial new options for managing resistant bacterial pneumonia.
- These agents offer improved efficacy, safety, and treatment flexibility.
- Continued development of new antimicrobials is essential to combat rising resistance.
More Related Videos
Related Concept Videos
00:57Antibiotic Selection
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Development of Antibiotic Resistance